BioSpace News Archive

Shockwave Medical, Inc. reported financial results for the three months and full year ended December 31, 2022.

Annexon, Inc. announced that it has granted equity inducement awards to four new non-executive employees under the terms of the 2022 Employment Inducement Award Plan.

Ascendis Pharma A/S announced financial results for the full year ended December 31, 2022 and provided a business update.

Penumbra, Inc. announced that its management team is scheduled to present at Citi’s 2023 Healthcare Services, Medtech, Tools & HCIT Conference on Thursday, March 2, 2023.

Blue Earth Diagnostics announced additional results from its Phase 3 LIGHTHOUSE trial that evaluated the diagnostic performance and safety of 18F-rhPSMA-7.3 in newly diagnosed prostate cancer.

IVERIC bio, Inc. announced that the U.S. Food and Drug Administration has completed its filing review and accepted the company’s New Drug Application for avacincaptad pegol, a novel investigational complement C5 inhibitor for the treatment of geographic atrophy secondary to Age-Related Macular Degeneration.

VolitionRx Limited, a multi-national epigenetics company, announced that it has commenced an underwritten public offering of shares of its common stock.

Travere Therapeutics, Inc. announced it will report fourth quarter and full year 2022 financial results on Thursday, February 23, 2023, after the close of the U.S. financial markets.

Alterity Therapeutics announced that the Company has been granted authorization to conduct its Phase 2 clinical trial for ATH434 in Multiple System Atrophy by the Austrian Federal Office for Safety in Healthcare and the French National Agency for the Safety of Medicine and Health Products.

Puma Biotechnology, Inc., a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, March 2, 2023, following the release of its fourth quarter and full year 2022 financial results.